Markus Warmuth

CIK: 0001855643

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (83.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GLUE

Monte Rosa Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

GLUE
Monte Rosa Therapeutics, Inc.
Jul 16, 2026
Sale(S)
Direct
9.5K shares at avg. $23.18$220K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 1, 2026
Sale(S)
Direct
5K shares at avg. $19.41$97K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 1, 2026
Sale(S)
Direct
468 shares at avg. $19.73$9K
GLUE
Monte Rosa Therapeutics, Inc.
May 1, 2026
Sale(S)
Direct
5.5K shares at avg. $18.92$103K
GLUE
Monte Rosa Therapeutics, Inc.
Apr 14, 2026
Sale(S)
Direct
8K shares at avg. $17.64$141K
GLUE
Monte Rosa Therapeutics, Inc.
Mar 2, 2026
Sale(S)
Direct
5.5K shares at avg. $17.92$98K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 7, 2026
Sale(S)
Direct
1.5K shares at avg. $23.88$35K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 7, 2026
Sale(S)
Direct
3.7K shares at avg. $23.24$86K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 7, 2026
Sale(S)
Direct
309 shares at avg. $24.57$8K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
10.1K shares at avg. $15.17$154K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
90K shares-
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2025
Award(A)
Direct
128K shares-

		Type	Shares	Price		Ownership
Jul 16, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	9,500	$23.18	$220,219	Direct
Jun 1, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	4,998	$19.41	$97,021	Direct
Jun 1, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	468	$19.73	$9,232	Direct
May 1, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	5,467	$18.92	$103,447	Direct
Apr 14, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	8,000	$17.64	$141,125	Direct
Mar 2, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	5,466	$17.92	$97,974	Direct
Jan 7, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	1,450	$23.88	$34,620	Direct
Jan 7, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	3,707	$23.24	$86,159	Direct
Jan 7, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	309	$24.57	$7,593	Direct
Jan 5, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	10,135	$15.17	$153,748	Direct
Jan 2, 2026	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	90,000	-	$0	Direct
Jan 2, 2025	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	128,000	-	$0	Direct

1-12 of 12 transactions

About Warmuth Markus

Warmuth Markus (SEC CIK 0001855643) files insider reports with the SEC as President & CEO of Monte Rosa Therapeutics, Inc. (GLUE).

Signal8 holds 8 ownership filings by Warmuth Markus, all Form 4s, filed between Jan 6, 2025 and Jul 17, 2026. Those filings report 12 transactions, from Jan 2, 2025 to Jul 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Warmuth Markus's filings is in BOSTON, MA.

Recent filings by Warmuth Markus

Jul 16, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jun 1, 2026: Open-market sales of GLUE shares (2 lines, Form 4, code S).
May 1, 2026: Open-market sale of GLUE shares (Form 4, code S).
Apr 14, 2026: Open-market sale of GLUE shares (Form 4, code S).
Mar 2, 2026: Open-market sale of GLUE shares (Form 4, code S).

Other insiders filing for Monte Rosa Therapeutics, Inc. (GLUE)

Bowen Matthew, Principal Accounting Officer
Champoux Jennifer, Chief Operating Officer
Townson Sharon, Chief Scientific Officer
Behbahani Ali, Director
Janku Filip, Chief Medical Officer
SCHIFF ANDREW N, Director

How to read Form 4 transaction codes